1y return+78.7%S&P 500 +20.9%
3y return+126.4%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2021: $152 against $157 in the S&P 500.2
SR One Capital Management, LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| MANEVeradermics, Inc. | $295.3M | 28.4% | |
| ZBIOZenas BioPharma, Inc | $127.9M | 12.3% | |
| CRISPR Therapeutics AGCUSIP H17182108 | $111.2M | 10.7% | |
| AVLNAvalyn Pharma, Inc | $108.9M | 10.5% | New |
| DSGNDesign Therapeutics, Inc. | $94.4M | 9.1% | |
| ODTXOdyssey Therapeutics, Inc. | $71.0M | 6.8% | New |
| ALMSAlumis Inc. | $55.2M | 5.3% | |
| ORICORIC Pharmaceuticals, Inc. | $50.0M | 4.8% | +2.2% |
| MLYSMineralys Therapeutics Inc. | $42.2M | 4.1% | |
| SPRYARS Pharmaceuticals, Inc. | $32.1M | 3.1% | |
| MOBIMobia Medical, Inc | $26.6M | 2.6% | New |
| NKTXNkarta, Inc. | $9.4M | 0.9% | |
| Oculis Holding AGCUSIP H5870P102 | $8.9M | 0.9% | |
| RAREUltragenyx Pharmaceutical Inc. | $4.6M | 0.4% | |
| enGene Holdings Inc.CUSIP 29286M105 | $1.3M | 0.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ALMSAlumis Inc. | June 30, 2024 | +111.6% | $55.2M |
| MANEVeradermics, Inc. | March 31, 2026 | +94.7% | $295.3M |
| MLYSMineralys Therapeutics Inc. | March 31, 2023 | +72.3% | $42.2M |
| ZBIOZenas BioPharma, Inc | September 30, 2024 | +50.0% | $127.9M |
| RAREUltragenyx Pharmaceutical Inc. | December 31, 2025 | +45.2% | $4.6M |
| ORICORIC Pharmaceuticals, Inc. | June 30, 2025 | +6.7% | $50.0M |
| SPRYARS Pharmaceuticals, Inc. | December 31, 2022 | −6.1% | $32.1M |
| CRISPR Therapeutics AGCUSIP H17182108 | March 31, 2024 | −20.0% | $111.2M |
| Oculis Holding AGCUSIP H5870P102 | March 31, 2025 | −27.1% | $8.9M |
| DSGNDesign Therapeutics, Inc. | December 31, 2021 | −32.4% | $94.4M |
Sold off last quarter
- Arcellx, Inc.CUSIP 03940C100 was $269.4M
- ORKAOruka Therapeutics, Inc was $21.1M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +10.7% | +14.8% |
| March 31, 2026 | +8.1% | −4.6% |
| December 31, 2025 | +2.9% | +2.4% |
| September 30, 2025 | +45.2% | +7.8% |
| June 30, 2025 | +6.7% | +10.5% |
| March 31, 2025 | −10.9% | −4.6% |
| December 31, 2024 | −18.2% | +2.1% |
| September 30, 2024 | +26.7% | +5.4% |
| June 30, 2024 | −21.6% | +4.0% |
| March 31, 2024 | +35.9% | +10.0% |
| December 31, 2023 | +43.2% | +11.2% |
| September 30, 2023 | −15.9% | −3.6% |
| June 30, 2023 | +4.7% | +8.3% |
| March 31, 2023 | −14.6% | +7.0% |
| December 31, 2022 | +9.3% | +7.1% |
| September 30, 2022 | +7.1% | −5.3% |
| June 30, 2022 | −3.8% | −16.5% |
| March 31, 2022 | −33.2% | −4.9% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: SR One Capital Management, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1910264&type=13F-HR&dateb=&owner=include&count=40CIK 1910264
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1910264/000119312526347065/Filed August 12, 2026 · accession 0001193125-26-347065